US Bancorp DE Has $77,000 Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

US Bancorp DE lessened its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVAGet Rating) by 10.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,194 shares of the company’s stock after selling 1,139 shares during the period. US Bancorp DE’s holdings in Teva Pharmaceutical Industries were worth $77,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of TEVA. Aaron Wealth Advisors LLC bought a new position in shares of Teva Pharmaceutical Industries during the first quarter worth about $603,000. Evolution Wealth Advisors LLC bought a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth approximately $94,000. Quantbot Technologies LP acquired a new stake in shares of Teva Pharmaceutical Industries in the first quarter valued at approximately $110,000. Atlas Capital Advisors LLC lifted its position in shares of Teva Pharmaceutical Industries by 18.6% in the first quarter. Atlas Capital Advisors LLC now owns 12,677 shares of the company’s stock worth $119,000 after purchasing an additional 1,987 shares in the last quarter. Finally, Sequoia Financial Advisors LLC boosted its holdings in Teva Pharmaceutical Industries by 15.6% during the first quarter. Sequoia Financial Advisors LLC now owns 12,690 shares of the company’s stock worth $119,000 after purchasing an additional 1,713 shares during the last quarter. Institutional investors and hedge funds own 46.22% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock opened at $9.08 on Thursday. The stock has a market cap of $10.08 billion, a P/E ratio of -7.83, a price-to-earnings-growth ratio of 3.31 and a beta of 1.27. Teva Pharmaceutical Industries Limited has a 1 year low of $6.78 and a 1 year high of $11.34. The company has a current ratio of 0.99, a quick ratio of 0.66 and a debt-to-equity ratio of 1.94. The stock has a 50 day simple moving average of $8.53 and a 200 day simple moving average of $8.59.

Teva Pharmaceutical Industries (NYSE:TEVAGet Rating) last released its earnings results on Thursday, November 3rd. The company reported $0.56 earnings per share for the quarter, missing analysts’ consensus estimates of $0.58 by ($0.02). Teva Pharmaceutical Industries had a negative net margin of 8.52% and a positive return on equity of 26.97%. The company had revenue of $3.60 billion for the quarter, compared to the consensus estimate of $3.86 billion. On average, research analysts predict that Teva Pharmaceutical Industries Limited will post 2.44 earnings per share for the current fiscal year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, CFO Eliyahu Sharon Kalif sold 55,500 shares of the company’s stock in a transaction that occurred on Monday, August 22nd. The shares were sold at an average price of $10.07, for a total transaction of $558,885.00. Following the completion of the sale, the chief financial officer now owns 9,376 shares of the company’s stock, valued at approximately $94,416.32. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.82% of the company’s stock.

Wall Street Analysts Forecast Growth

TEVA has been the topic of a number of recent research reports. Bank of America raised Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and lifted their target price for the company from $10.00 to $13.00 in a research report on Friday, August 5th. UBS Group cut Teva Pharmaceutical Industries from a “neutral” rating to a “sell” rating in a research note on Friday, November 4th. Jefferies Financial Group reaffirmed a “buy” rating and set a $10.00 price objective on shares of Teva Pharmaceutical Industries in a research report on Friday, October 21st. StockNews.com began coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, October 12th. They set a “buy” rating for the company. Finally, BMO Capital Markets decreased their price target on shares of Teva Pharmaceutical Industries from $11.00 to $10.00 and set a “market perform” rating on the stock in a research note on Monday. Two analysts have rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of “Hold” and an average target price of $10.50.

About Teva Pharmaceutical Industries

(Get Rating)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.

Further Reading

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.